| PATHEON-UK-LIMITED |
PATHEON-UK-LIMITED |
85%
|
A”) with Patheon UK Limited (“Patheon”), a subsidiary of Thermo Fisher Scientific Inc., for certain manufacturing and quality control services. The Agreement contains customary termination and cancel… |
| TMO |
Thermo Fisher Scientific Inc. |
85%
|
Reciprocal relationship from TMO graph: Reciprocal relationship from IMTX graph: Reciprocal relationship from TMO graph: Reciprocal relationship from IMTX graph: Reciprocal relationship from TMO grap… |
| TMO |
Thermo Fisher Scientific Inc. |
85%
|
A”) with Patheon UK Limited (“Patheon”), a subsidiary of Thermo Fisher Scientific Inc., for certain manufacturing and quality control services. The Agreement contains customary termination and cancel… |
| EDIT |
Editas Medicine, Inc. |
72%
|
expired Service Options outstanding on December 31, Service Options exercisable on December 31, Weighted average remaining contract life (years) Service Options outstanding as of December 31, 2022: F… |
| EDIT |
Editas Medicine, Inc. |
72%
|
Reciprocal relationship from EDIT graph: Reciprocal relationship from IMTX graph: expired Service Options outstanding on December 31, Service Options exercisable on December 31, Weighted average rema… |
| GDTC |
CytoMed Therapeutics Limited |
72%
|
Reciprocal relationship from GDTC graph: l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any n… |
| GNMSF |
Genmab A/S |
72%
|
future taxable profits together with future tax planning strategies. Due to the Group’s history of loss-making over the last several years as well as the plans for the foreseeable future, the Group h… |
| GNMSF |
Genmab A/S |
72%
|
Reciprocal relationship from GNMSF graph: Reciprocal relationship from IMTX graph: Reciprocal relationship from GNMSF graph: Reciprocal relationship from IMTX graph: Reciprocal relationship from GNMS… |
| MRNA |
Moderna, Inc. |
72%
|
Reciprocal relationship from MRNA graph: tablished a global Environment, Health, and Safety (EHS) organization to foster a safe and healthy work environment with a focus on sustainability and complia… |
| ADVANCED-TCER-ACTIVITIES-THE-GROUP |
ADVANCED-TCER-ACTIVITIES-THE-GROUP |
62%
|
ontain elements of a customer relationship even though it is a collaboration agreement, where to some degree both risks and benefits are shared between the Group and Moderna. They clearly state deliv… |
| ARYA-SCIENCES-ACQUISITION-CORP |
ARYA-SCIENCES-ACQUISITION-CORP |
62%
|
protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. • Federal civil and criminal fal… |
| ARYA-SCIENCES-HOLDINGS |
ARYA-SCIENCES-HOLDINGS |
62%
|
protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. • Federal civil and criminal fal… |
| AVERILL-MASTER-FUND-LTD |
AVERILL-MASTER-FUND-LTD |
62%
|
shares held by Baker Brothers Life Sciences, L.P. and 667, L.P. (collectively, the “Funds”). The Funds’ respective general partners relinquished to Baker Bros. Advisors LP (the “Adviser”). Baker Bros… |
| BIONTECH-RNA-PHARMACEUTICALS-GMBH |
BIONTECH-RNA-PHARMACEUTICALS-GMBH |
62%
|
each year presented: Year ended December 31, 2025 2024 2023 (Euros in thousands, except per share data) Revenue from collaboration agreements 48,266 155,835 53,997 Research and development expenses (… |
| FOR-IMMATICS-GMBH |
FOR-IMMATICS-GMBH |
62%
|
2.2 mill ion, € 1.6 million and € 0.5 million, respectively. For the years ended December 31, 2025, 2024 and 2023, other employee benefits also include employee health insurance costs amounting to € … |
| FRESENIUS-BIOTECH-GMBH |
FRESENIUS-BIOTECH-GMBH |
62%
|
each year presented: Year ended December 31, 2025 2024 2023 (Euros in thousands, except per share data) Revenue from collaboration agreements 48,266 155,835 53,997 Research and development expenses (… |
| GERMANY-THE-GROUP |
GERMANY-THE-GROUP |
62%
|
edures also included, among others (i) testing the actual costs incurred to date for each identified performance obligation; (ii) evaluating and testing management’s process for estimating total cost… |
| GP-LLC |
GP-LLC |
62%
|
shares held by Baker Brothers Life Sciences, L.P. and 667, L.P. (collectively, the “Funds”). The Funds’ respective general partners relinquished to Baker Bros. Advisors LP (the “Adviser”). Baker Bros… |
| IMMATICS-BIOTECHNOLOGIES-GMBH |
IMMATICS-BIOTECHNOLOGIES-GMBH |
62%
|
ontain elements of a customer relationship even though it is a collaboration agreement, where to some degree both risks and benefits are shared between the Group and Moderna. They clearly state deliv… |
| IMMATICS-GMBH |
IMMATICS-GMBH |
62%
|
tanding on December 31, 2024 10.09 3,680,000 PSUs exercisable on December 31, 2024 — — Weighted average remaining contract life (years) 5.60 PSUs outstanding as of December 31, 2023: 2023 Weighted av… |
| IMMATICS-GMBH-THE-GROUP |
IMMATICS-GMBH-THE-GROUP |
62%
|
2.2 mill ion, € 1.6 million and € 0.5 million, respectively. For the years ended December 31, 2025, 2024 and 2023, other employee benefits also include employee health insurance costs amounting to € … |
| IMMATICS-US-INC |
IMMATICS-US-INC |
62%
|
2.2 mill ion, € 1.6 million and € 0.5 million, respectively. For the years ended December 31, 2025, 2024 and 2023, other employee benefits also include employee health insurance costs amounting to € … |
| PASSIVE-FOREIGN-INVESTMENT-COMPANY |
PASSIVE-FOREIGN-INVESTMENT-COMPANY |
62%
|
shares held by Baker Brothers Life Sciences, L.P. and 667, L.P. (collectively, the “Funds”). The Funds’ respective general partners relinquished to Baker Bros. Advisors LP (the “Adviser”). Baker Bros… |
| PERCEPTIVE-ADVISORS-LLC |
PERCEPTIVE-ADVISORS-LLC |
62%
|
shares held by Baker Brothers Life Sciences, L.P. and 667, L.P. (collectively, the “Funds”). The Funds’ respective general partners relinquished to Baker Bros. Advisors LP (the “Adviser”). Baker Bros… |
| PERCEPTIVE-LIFE-SCIENCES-MASTER-FUND-LTD |
PERCEPTIVE-LIFE-SCIENCES-MASTER-FUND-LTD |
62%
|
shares held by Baker Brothers Life Sciences, L.P. and 667, L.P. (collectively, the “Funds”). The Funds’ respective general partners relinquished to Baker Bros. Advisors LP (the “Adviser”). Baker Bros… |
| PRICEWATERHOUSECOOPERS-GMBH |
PRICEWATERHOUSECOOPERS-GMBH |
62%
|
edures also included, among others (i) testing the actual costs incurred to date for each identified performance obligation; (ii) evaluating and testing management’s process for estimating total cost… |
| SUVRETTA-CAPITAL-MANAGEMENT-LLC |
SUVRETTA-CAPITAL-MANAGEMENT-LLC |
62%
|
shares held by Baker Brothers Life Sciences, L.P. and 667, L.P. (collectively, the “Funds”). The Funds’ respective general partners relinquished to Baker Bros. Advisors LP (the “Adviser”). Baker Bros… |
| VOTING-INTEREST-IMMATICS-BIOTECHNOLOGIES-GMBH |
VOTING-INTEREST-IMMATICS-BIOTECHNOLOGIES-GMBH |
62%
|
terms. Each project under the MSA will be governed by a specific project agreement. Upon the entry of the MSA, the parties entered into a project agreement that provides for the manufacturing of IMA4… |
